RecruitingPhase 1Phase 2NCT06347718

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

Sponsor

Miltenyi Biomedicine GmbH

Enrollment

24 participants

Start Date

Jul 17, 2023

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus Dermatomyositis Polymyositis Systemic Sclerosis

Summary

The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During treatment, patients undergo leukapheresis, lymophodepleting chemotherapy and administration of the expanded CD19-CAR-transduced T cells.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called anti-CD19 CAR T cell therapy for people with dermatomyositis, polymyositis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.